£90 MILLION of funding has been channelled into the development of a new cancer drug; known as a POLQ inhibitor, it specifically targets cancer cells with the mutated BRCA genes, while leaving healthy cells unharmed.
You Can See More: Cancer treatment: 'Exciting' new drug targets tumours created by faulty BRCA genes
The following article Cancer treatment: 'Exciting' new drug targets tumours created by faulty BRCA genes is courtesy of Daily Express :: Health Feed
£90 MILLION of funding has been channelled into the development of a new cancer drug; known as a POLQ inhibitor, it specifically targets cancer cells with the mutated BRCA genes, while leaving healthy cells unharmed.
£90 MILLION of funding has been channelled into the development of a new cancer drug; known as a POLQ inhibitor, it specifically targets cancer cells with the mutated BRCA genes, while leaving healthy cells unharmed.
0 comments:
Post a Comment
Note: Only a member of this blog may post a comment.